Evidence for the Use of biological therapies in ulcers of the foot in diabetes

BioDrugs

Volumn 28, Issue 1, 2014, Pages 1-6

  Jeffcoate, William J ^a   Game, Frances L ^b  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b DERBY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECAPLERMIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; VASCULOTROPIN;

BIOLOGICAL THERAPY; CHRONIC WOUND; CLINICAL TRIAL; DIABETES MELLITUS; FIBROBLAST CULTURE; FOOT ULCER; HUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL; WOUND CARE; WOUND HEALING; WOUND HEALING IMPAIRMENT;

BIOENGINEERING; CELLS, CULTURED; COCULTURE TECHNIQUES; COLLAGEN; DIABETIC FOOT; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; HUMANS; KERATINOCYTES; PROTO-ONCOGENE PROTEINS C-SIS; STEM CELLS; TISSUE EXPANSION DEVICES;

EID: 84895748191     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-013-0052-3     Document Type: Review

References (39)

1. Bornstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol. 2002;14:608-16.
2. Schultz GS, Davidson JM, Kirsner RS, Bornstein P, Herman IM. Dynamic reciprocity in the wound microenvironment. Wound Repair Regen. 2011;19:134-8.
3. Brandner JM, Zacheja S, Houdek P, Moll I, Lobmann R. Expression of matrix metalloproteinases, cytokines, connexins in diabetic and nondiabetic human keratinocytes before and after transplantation into an ex vivo wound-healing model. Diabetes Care. 2008;2008(31):114-20.
4. Londahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care. 2010;33:998-1003.
5. Kranke P, Bennett MH, Martyn-St James M, Schnabel A, Debus SE. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst Rev. 2012;4:CD004123. doi: 10.1002/14651858.CD004123.pub3.
6. Lipsky BA, Berendt AR. Hyperbaric oxygen therapy for diabetic foot wounds: has hope hurdled hype? Diabetes Care. 2010;33:1143-5.
7. Peinemann F, McGaurin N, Sauerland A, Langer S. Negative pressure wound therapy: potential publication bias caused by lack of access to unpublished study results data. BMC Med Res Methodol. 2008;8:4. doi: 10.1186/1471-2288-8-4.
8. National Institute for Clinical Excellence. Diabetic foot problems: inpatient management of diabetic foot problems. http://www.nice.org.uk/ nicemedia/live/13416/53558/53558.pdf Accessed 29 Jan 2013.
9. Hinchliffe RJ, Valk GD, Apelqvist J, Armstrong DG, Bakker K, Game FL, et al. A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev. 2008;24(Suppl 1):S188-9. doi: 10.1002/dmrr.854.
10. Game FL, Hinchliffe RJ, Apelqvsit J, Armstrong DG, Bakker K, Hartemann A. A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev. 2012;28(Suppl 1):119-41. doi: 10.1002/dmrr.2246.
11. Dumville JC, Soares MO, O'Meara S, Cullum N. Systematic review and mixed treatment comparison: dressings to heal diabetic foot ulcers. Diabetologia. 2012;55:1902-10.
12. GRADE Working Group. Frequently asked questions. http://www. gradeworkinggroup.org/FAQ/index.htm Accessed 29 Jan 2013.
13. SIGN. Methodology. http://www.sign.ac.uk/methodology/index.html Accessed 29 Jan 2013.
14. Veves A, Sheehan P, Pham HT. A randomized controlled trial of Promogran (a collagen/oxidized cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg. 2002;137:822-7.
15. Motzkau M, Tautenhahn J, Lehnert H, Lobmann R. Expression of matrix-metalloproteinases in the fluid of chronic diabetic foot wounds treated with a protease absorbent dressing. Exp Clin Endocrinol Diabetes. 2011;119:286-90.
16. Blume P, Driver VR, Tallis AJ, Kirsner RS, Kroeker R, Payne WG, et al. Formulated collagen gel accelerates healing rate immediately after application in patients with diabetic neuropathic ulcers. Wound Repair Regen. 2011;19:302-8.
17. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: a phase III randomized placebo-controlled double-blind study. Diabetes Care. 1998;21:822-7.
18. Richard JL, Parer-Richard C, Daures JP, Clouet S, Vannereau D, Bringer J, et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: a pilot, double-blind, randomized, placebo-controlled study. Diabetes Care. 1995;18:64-9.
19. Uchi H, Igarashi A, Urabe K, Koga T, Makayama J, Kawamori R, et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. Eur J Dermatol. 2009;19:461-8.
20. Fernández-Montequín JI, Valenzuela-Silva CM, Díaz OG, Savigne W, Sancho-Soutelo N, Rivero-Fernández F, et al. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study. Int Wound J. 2009;6:432-43.
21. Valenzuela-Silva CM, Tuero-Iglesias AD, Garcia-Iglesias E, González-Diaz O, Del Rio-Martin A, Year Alos IB, Fernández- Montequín JL, López-Saura PA. Granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant human epidermal growth factor. Diabetes Care. 2013;36:210-5 (Epub 12 Sep 2012).
22. Kusumanto YH, van Weel V, Mulder NH, Smit AJ, van den Dungen JJ, Hooymans JM, et al. Treatment with intramuscular growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther. 2006;17:683-91.
23. Cruciani M, Lipsky BA, Mengoli C, de Lalla F. Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections. Cochrane Database Syst Rev. 2009;3:CD006810. doi: 10.1002/146511858.CD006810.pub2.
24. Jackson WM, Nest LJ, Tuan RS. Concise review: clinical translation of wound healing therapies based on mesenchymal stem cells. Stem Cells Trans Med. 2012;1:44-50.
25. Seung-Kyu H, Hong-Surk K, Woo-Kyung K. The treatment of diabetic foot ulcers with uncultured, processed lipoaspirate cells: a pilot study. Wound Repair Regen. 2010;18:342-6.
26. Idei N, Soga J, Hata T, Fujii Y, Fujimara N, Mikami S, et al. Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial and Buerger disease. Circ Cardiovasc Interv. 2011;4:15-25.
27. Lu D, Chen B, Liang Z, Deng W, Jiang Y, Li S, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract. 2011;92:26-36.
28. Kirana S, Stratmann B, Prante C, Prohaska W, Koeperich H, Lammers D, et al. Autologous stem cell therapy in the treatment of limb ischaemia induced chronic tissue ulcers of diabetic foot patients. Int J Clin Pract. 2012;66:384-93.
29. Lacci KM, Dardik A. Platelet-rich plasma: support for its use in wound healing. Yale J Biol Med. 2010;83:1-9.
30. Marston WA, Hanft J, Norwood P, Pollak R, Dermagraft Diabetic Foot Ulcer Study Group. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. 2003;26:1701-5.
31. Veves A, Falanga V, Armstrong DG, Sabolinski ML, Apligraf Diabetic Foot Ulcer Study Group. Graftskin, a human skin equivalent, is effective in the management of non-infected diabetic foot ulcers: a prospective randomized multicentre clinical trial. Diabetes Care. 2001;24:290-5.
32. Edmonds M, European and Australian Apligraf Diabetic Foot Ulcer Study Group. Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds. 2009;8:11-8.
33. Armstrong DG, Lavery LA, Wu S, Boulton AJ. Evaluation of removable and irremovable cast walkers: a randomized controlled trial. Diabetes Care. 2005;28:551-4.
34. Uccioli L, Giurato L, Ruotolo V, Ciavarella A, Grimaldi MS, Piaggesi A, et al. Two-step autologous grafting using HYAFF scaffolds in treating diabetic foot ulcers: results of a multicenter, randomized controlled clinical trial with long-term follow-up. Int J Low Extrem Wounds. 2011;10:80-5.
35. Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. Diabetic neuropathic foot ulcers: the association of wound size, wound duration, and wound grade on healing. Diabetes Care. 2002;25:1835-9.
36. Ince P, Game FL, Jeffcoate WJ. Rate of healing of neuropathic ulcers of the foot in diabetes and its relationship to ulcer duration and ulcer area. Diabetes Care. 2007;30:660-3.
37. Krishnan S, Nash F, Baker N, Fowler D, Rayman G. Reduction in diabetic amputations over 11 years in a defined U.K. population: benefits of multidisciplinary team work and continuous prospective audit. Diabetes Care. 2008;31:99-101.
38. Canavan RJ, Unwin NC, Kelly WF, Connolly VM. Diabetes- and nondiabetes-related lower extremity amputation incidence before and after the introduction of better organized diabetes foot care: continuous longitudinal monitoring using a standard methods. Diabetes Care. 2008;31:459-63.
39. Kennon B, Leese GP, Cochrane L, Colhoun H, Wild S, Stang D, et al. Reduced incidence of lower-extremity amputations in people with diabetes in Scotland: a nationwide study. Diabetes Care. 2012;35:2588-90.